Dambkowski Carl 4

What Happened

• Carl Dambkowski, a director of Oruka Therapeutics, reported an other acquisition/disposition (code J) on 2026-01-23 in which he received 116,483 shares of Oruka common stock.
• The shares were reported at $0.00 per share (total $0) as they were distributed pro‑rata from an LLC in which he is a member.

Key Details

• Transaction date: 2026-01-23; Report filed: 2026-01-23 (timely).
• Reported price: $0.00 per share; Total reported value: $0.
• Footnote: The shares were a pro‑rata distribution of common stock for no consideration from an LLC of which the reporting person is a member.
• Shares owned after the transaction: Not stated in the provided filing.
• Transaction type code: J (other acquisition/disposition) — not an open‑market purchase, sale, or option exercise.

Context

• This was a non‑cash distribution from an LLC, not an open‑market purchase or a sale. Such distributions often reflect internal allocation of equity rather than a buy/sell signal; they do not by themselves indicate the insider’s view of the company’s stock price.
• Retail investors should treat this as an ownership change disclosed for transparency; it’s factual reporting rather than a traditional purchase or sale transaction.